Stockscreener 앱 받기
35.95
5.06%
1.73
시간 외 거래:
36.16
0.21
+0.58%
전일 마감가:
$34.22
열려 있는:
$34.2
하루 거래량:
1.10M
Relative Volume:
0.75
시가총액:
$6.64B
수익:
$520.18M
순이익/손실:
$-348.13M
주가수익비율:
-18.72
EPS:
-1.92
순현금흐름:
$-176.18M
1주 성능:
+3.54%
1개월 성능:
-7.35%
6개월 성능:
+9.01%
1년 성능:
-37.29%
1일 변동 폭
$34.14
$36.17
1주일 범위
$34.14
$36.17
52주 변동 폭
$27.34
$57.94
Legend Biotech Corp Adr Stock (LEGN) Company Profile
LEGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
35.95 | 6.41B | 520.18M | -348.13M | -176.18M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.62 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.43 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
722.01 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.26 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-06-17 | 개시 | Truist | Buy |
| 2024-05-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-05-23 | 개시 | Deutsche Bank | Buy |
| 2024-04-17 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | Raymond James | Outperform |
| 2023-12-19 | 개시 | Scotiabank | Sector Perform |
| 2023-11-06 | 개시 | Goldman | Buy |
| 2023-05-25 | 개시 | William Blair | Mkt Perform |
| 2023-05-22 | 개시 | Daiwa Securities | Buy |
| 2023-03-29 | 개시 | H.C. Wainwright | Buy |
| 2023-03-24 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-11-02 | 개시 | Evercore ISI | Outperform |
| 2022-11-01 | 개시 | Cowen | Outperform |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-03-15 | 개시 | Barclays | Overweight |
| 2022-01-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2020-07-01 | 개시 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Morgan Stanley | Overweight |
모두보기
Legend Biotech Corp Adr 주식(LEGN)의 최신 뉴스
Legend Biotech’s SWOT analysis: carvykti success drives stock potential amid challenges - Investing.com
Brokers Issue Forecasts for Legend Biotech FY2025 Earnings - Defense World
Legend Biotech (NASDAQ:LEGN) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
170,186 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Nuveen LLC - Defense World
Legend Biotech (NASDAQ:LEGN) Price Target Raised to $78.00 at JPMorgan Chase & Co. - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives $72.38 Average PT from Brokerages - Defense World
PNC Financial Services Group Inc. Buys 3,238 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Legend Biotech Corporation Sponsored ADR $LEGN Stock Holdings Boosted by Swiss National Bank - Defense World
US Bancorp DE Lowers Position in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Legend Biotech names Carlos Santos as new CFO - Investing.com
Legend Biotech’s SWOT analysis: carvykti drives growth as stock faces competition - Investing.com
Legend Biotech’s SWOT analysis: carvykti drives growth as stock faces competition By Investing.com - Investing.com South Africa
Company News for Aug 12, 2025 - NewsBreak: Local News & Alerts
Legend Biotech (NASDAQ:LEGN) Price Target Raised to $83.00 at Morgan Stanley - Defense World
Legend Biotech (NASDAQ:LEGN) Receives Outperform Rating from Royal Bank Of Canada - Defense World
Legend Biotech stock price target raised to $77 by RBC Capital - Investing.com South Africa
Earnings call transcript: Legend Biotech Q2 2025 reveals strong revenue growth - Investing.com
Earnings call transcript: Legend Biotech Q2 2025 reveals strong revenue growth By Investing.com - Investing.com South Africa
Legend Biotech Q2 2025 slides: CARVYKTI sales surge 136%, adjusted profit achieved - Investing.com India
XTX Topco Ltd Takes $307,000 Position in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
Legend Biotech on Track for Record Losing Streak — Data Talk - Morningstar
Cantor Fitzgerald Estimates Legend Biotech FY2025 Earnings - Defense World
Brokerages Set Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Price Target at $73.33 - Defense World
Bank of New York Mellon Corp Has $4.55 Million Stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
HC Wainwright Forecasts Legend Biotech Q2 Earnings - Defense World
Legend Biotech’s (LEGN) Buy Rating Reiterated at HC Wainwright - Defense World
Q1 EPS Estimates for Legend Biotech Raised by HC Wainwright - Defense World
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains? - Yahoo Finance
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com India
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. Wainwright reiterates Buy rating on Legend Biotech stock after strong CARVYKTI sales - Investing.com India
Goldman Sachs reiterates buy rating on Legend Biotech stock after strong Carvykti sales - Investing.com India
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Shares Acquired by GAMMA Investing LLC - Defense World
Legend Biotech stock price target lowered to $54 at UBS on growth concerns - Investing.com
Legend Biotech stock maintains Buy rating as FDA eases CARVYKTI restrictions - Investing.com
Bristol Myers, Gilead, J&J, Novartis win favorable FDA label updates for cell therapies - Seeking Alpha
Legend Biotech’s SWOT analysis: carvykti’s strong performance drives stock potential By Investing.com - Investing.com South Africa
Legend Biotech’s SWOT analysis: carvykti’s strong performance drives stock potential - Investing.com India
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Barchart.com
Oracle and GameStop Headline Market Cap Stock Movers on Thursday By Investing.com - Investing.com South Africa
Eli Lilly, General Electric among Tuesday’s market cap stock movers By Investing.com - Investing.com India
Eli Lilly, General Electric among Tuesday’s market cap stock movers - Investing.com
CARVYKTI shows lasting impact in multiple myeloma treatment By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating on Legend Biotech stock By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating on Legend Biotech stock - Investing.com India
BMO Capital reaffirms outperform rating on Legend Biotech stock By Investing.com - Investing.com South Africa
BMO Capital reaffirms outperform rating on Legend Biotech stock - Investing.com India
RBC Capital maintains Legend Biotech at outperform with $78 target By Investing.com - Investing.com South Africa
RBC Capital maintains Legend Biotech at outperform with $78 target - Investing.com
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com South Africa
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday - Investing.com
Legend Biotech Corp Adr (LEGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.14%
1.34%
자본화:
|
볼륨(24시간):